It's Friday, September 18th. I'm Achilles Hughes.

And I'm Gideon Ressneck and this is what a day where we are finally processing our prime time,

any snub. Yeah, I know we didn't technically qualify for any of the categories, but it's still

stings. Look, tries we might, I guess what a day will never be the Kominsky method.

We've been trying.

On today's show, what Congress isn't doing on coronavirus and what it is doing on judges,

then some headlines. But first, the latest. And we're going to start with vaccine since promises

about when they might be available have been a really hot topic at the White House.

Earlier this week, we talked about AstraZeneca pausing and then restarting its phase three trial

in the UK. That and, you know, gestures and everything have caused a push for pharma companies

to be more transparent about their vaccine trials and the approval process overall. So now we're

seeing a little bit more from the companies about how these trials are working. So let's get into that.

That's right. So yesterday, Moderna, which is working on one of the more potentially promising

vaccines at the moment, released this extensive document that was aimed at explaining how its

late stage trials are going and what could come next. And as you said, the idea here is to release

more information as a way to gain public trust. So as a refresher quickly, Moderna's vaccine is

being developed with scientists at the National Institutes of Health and was the first to be tested

on humans. And this new information from Moderna came out in conjunction with a call to investors

about progress on their work. And so reportedly, the phase three trial has recruited more than 25,000

volunteers out of the 30,000 they're looking for. And the company's chief medical officer said the

rest should be enrolled in the next few weeks. Yeah. And what else to be learned about timing and

participants? So the New York Times write up of the report itself. They said that about 28% of the

...